The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...
Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs ...
New three-month data from a study of non-human primates underpins the biotech firm's decision to amend the small interfering RNA program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback